



Q: Who should receive the Lyme disease vaccine?

ALAN J. TAEGE, MD

Department of Infectious Diseases, Cleveland Clinic

A: ALTHOUGH LYME DISEASE is the most common vector-borne illness in the United States, not everyone needs to be immunized against it—not even in areas in which the *Ixodes* tick (which transmits the culprit spirochete *Borrelia burgdorferi*) is endemic.

When deciding if a patient is a candidate for the Lyme disease vaccine (LYMErix), we should not only consider geographic risk of infection, but also whether the patient's normal, everyday activities and behavior expose him or her to tick bites, and whether he or she has previously been exposed. Contrary to popular belief, Lyme disease is most often acquired near the home.

■ CRITERIA FOR VACCINATION

LYMErix, the first vaccine approved for the prevention of Lyme disease in the United States, is approved for use in people ages 15 to 70.

Prime candidates

The best candidates for Lyme disease vaccine are people who live in moderate-risk and high-risk areas (FIGURE 1) and whose work or recreation brings frequent or prolonged exposure to tick bites. People who travel to endemic areas and anticipate prolonged exposure are also candidates, provided there is adequate time to complete the vaccine schedule.

Children are the group with the highest rate of Lyme disease infection. Unfortunately, the current vaccine is not approved for use in children.

Previous infection does not always confer immunity. People who have already had Lyme disease and meet the above exposure criteria for vaccination should be vaccinated.

When is vaccination not recommended?

Due to a lack of data from randomized controlled trials, vaccination for Lyme disease is currently not recommended in the following groups:


- Pregnant women
- Children under age 15
- Adults over age 70.

In people undergoing treatment for treatment-resistant Lyme arthritis, the vaccine may cause an immune reaction that theoretically could worsen the arthritis, and therefore, vaccination is not recommended. People who live in a high-risk region but whose activities bring minimal or no exposure do not need vaccination.

■ VACCINE FACTS

The Lyme disease vaccine contains an outer surface protein of *B burgdorferi* grown in genet-


Regions of high, moderate, and low risk for Lyme disease




SOURCE: CENTERS FOR DISEASE CONTROL AND PREVENTION

FIGURE 1

THE CLEVELAND
CLINIC
FOUNDATION
DEPARTMENT of
CARDIOLOGY
PRESENTS



An Intensive Review of CARDIOLOGY



A COMPREHENSIVE

5½-DAY SYMPOSIUM

• • •

SEPTEMBER 24 - 29,

2000

MARRIOTT KEY

CENTER HOTEL,

CLEVELAND, OH

Co-Directors: Eric Topol, MD, Brian Griffin, MD,
and Curtis Rimmerman, MD

For more information, please contact the
Cleveland Clinic Center for Continuing
Education at

1-800-762-8173 or 216-444-5695

or visit our website:

www.clevelandclinicmeded.com

1-MINUTE CONSULT




ically modified *Escherichia coli*. Therefore, it poses no risk of iatrogenic infection.

Dosage. The vaccine is given in three intramuscular doses of 0.5 cc. After the first dose, the second is given at 1 month and the third at 12 months.

Side effects are generally minor and include discomfort at the injection site in 24% of patients and flulike symptoms (myalgia, fever, chills) in 3.2%.

Efficacy. The vaccine is not 100% effective. In two large clinical trials, efficacy was 49% to 68% after two doses and 76% to 92% after the third dose. After vaccination, tests for anti-*B burgdorferi* antibodies may become positive. Based on this information, it could be assumed that there is less than a 50% possibility of vaccine protection after the first dose. There appear to be no data concerning protection after the first dose.

Duration of immunity is not known, nor is the need for booster doses. As more is learned about the vaccine further recommendations will be issued concerning the need for revaccination. Currently, practitioners administer the three standard doses.

Cost. About \$60 per dose, with total cost to the patient depending on office fees. 

■ SUGGESTED READING

Appendix. Methods used for creating a national Lyme disease risk map. *MMWR* 1999; 48(RR07):21-24.

Dennis DT. Recommendations for the use of Lyme disease vaccine. *MMWR* 1999; 48(RR07):1-17.

Meltzer MI, Dennis DT, Orloski KA. The cost effectiveness of vaccinating against Lyme disease. *Emerg Infect Dis* 1999; 5:321-328.

Sigal LH. Myths and facts about Lyme disease. *Cleve Clin J Med* 1997; 64:203-209.

Sigal LH, Zahradnik JM, Lavin P, et al. A vaccine consisting of recombinant *Borrelia burgdorferi* outer-surface protein A to prevent Lyme disease. *N Engl J Med* 1998; 339:216-222.

Steere AC, Sikand VK, Meurice F, et al. Vaccination against Lyme disease with recombinant *Borrelia burgdorferi* outer-surface lipoprotein A with adjuvant. *N Engl J Med* 1998; 339:209-215.

Visit our web site at
<http://www.ccjm.org>

Contact us by e-mail at
ccjm@ccf.org